Sugi Predict

Sugi Predict / Compounds / SCHEMBL183693

SCHEMBL183693

SCHEMBL183693

CCOC(=O)C1CN(C(=O)OC(C)(C)C)CCCC1=O

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 3/20 0.44
▸ ALDH1A1 P00352 5/20 0.42
▸ HPGD P15428 3/20 0.42
▸ KDM4E B2RXH2 2/20 0.42
▸ HSD17B10 Q99714 2/20 0.42
▸ GLA P06280 1/20 0.42
▸ RECQL P46063 1/20 0.42
▸ MEN1 O00255 3/20 0.42
▸ KMT2A Q03164 3/20 0.42
▸ ADORA1 P30542 1/20 0.39
▸ TSHR P16473 1/20 0.39
▸ DDB1 Q16531 1/20 0.37
▸ CRBN Q96SW2 1/20 0.37
▸ GAA P10253 1/20 0.37
▸ NR1H2 P55055 1/20 0.37
▸ FEN1 P39748 1/20 0.37
▸ PREP P48147 1/20 0.36
▸ BACE1 P56817 2/20 0.36
▸ CTSD P07339 1/20 0.36
▸ CTSL P07711 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29974438 1.00 MAPT (0.44) MAPTALDH1A1HPGDKDM4EHSD17B10
SCHEMBL183637 0.92 MAPT (0.46) MAPTALDH1A1HPGDKDM4EHSD17B10
SCHEMBL29450286 0.92 MAPT (0.46) MAPTALDH1A1HPGDKDM4EHSD17B10
SCHEMBL4167125 0.89 HPGD (0.47) MAPTALDH1A1HPGDKDM4EHSD17B10
SCHEMBL17505316 0.88 ALDH1A1 (0.40) MAPTALDH1A1HPGDKDM4EHSD17B10
SCHEMBL1224464 0.84 MAPT (0.48) MAPTALDH1A1HPGDKDM4EHSD17B10
SCHEMBL30456334 0.84 MAPT (0.48) MAPTALDH1A1HPGDKDM4EHSD17B10
SCHEMBL1224468 0.84 MAPT (0.48) MAPTALDH1A1HPGDKDM4EHSD17B10
SCHEMBL4179680 0.84 HPGD (0.44) MAPTALDH1A1HPGDKDM4EHSD17B10
SCHEMBL23039821 0.83 MAPT (0.43) MAPTALDH1A1HPGDKDM4EHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230096028-A1 BICYCLIC HETEROCYCLYL COMPOUNDS AND USES THEREOF Revolution Medicines, Inc. 2023-03-30 — — US disclosed
EP-3930845-A1 BICYCLIC HETEROCYCLYL COMPOUNDS AND USES THEREOF Revolution Medicines, Inc. (US) 2022-01-05 — — EP disclosed
CN-113727758-A Bicyclic heterocyclic compounds and use thereof 锐新医药公司 2021-11-30 — — CN disclosed
WO-2018152286-A1 7-MEMBERED AZA-HETEROCYCLIC CONTAINING DELTA-OPIOID RECEPTOR MODULATING COMPOUNDS, METHODS OF USING AND MAKING THE SAME TREVENA, INC. (US) 2018-08-23 — — WO disclosed
EP-2376478-B1 PYRIDYLOXYINDOLES INHIBITORS OF VEGF-R2 AND USE THEREOF FOR TREATMENT OF DISEASE NOVARTIS AG (CH) 2017-04-19 — — EP disclosed
US-8829011-B2 2-aminopyrimidine compounds as serotonin receptor modulators JANSSEN PHARMACEUTICA NV (BE) 2014-09-09 — — US disclosed
US-8618288-B2 Pyrimidine compounds as serotonin receptor modulators JANSSEN PHARMACEUTICA NV (BE) 2013-12-31 — — US disclosed
US-8541432-B2 Heterobicyclic carboxamides as inhibitors for kinases NOVARTIS AG (CH) 2013-09-24 — — US disclosed
US-8501756-B2 Heterobicyclic carboxamides as inhibitors for kinases NOVARTIS AG (CH) 2013-08-06 — — US disclosed
US-8492393-B2 Heterobicyclic carboxamides as inhibitors for kinases NOVARTIS AG (CH) 2013-07-23 — — US disclosed
WO-2010066684-A2 Pyridyloxyindoles Inhibitors of VEGF-R2 and Use Thereof for Treatment of Disease NOVARTIS AG (CH) 2010-06-17 — — WO disclosed
WO-2010053825-A1 2-AMINOPYRIMIDINE COMPOUNDS AS SEROTONIN RECEPTOR MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2010-05-14 — — WO disclosed
US-20100016281-A1 PYRIMIDINE COMPOUNDS AS SEROTONIN RECEPTOR MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2010-01-21 — — US disclosed
US-7598255-B2 Pyrimidine compounds as serotonin receptor modulators JANSSEN PHARMACEUTICA NV (BE) 2009-10-06 — — US disclosed
EP-1928461-A1 PYRIMIDINE COMPOUNDS AS SEROTONIN RECEPTOR MODULATORS JANSSEN PHARMACEUTICA N.V. (BE) 2008-06-11 — — EP disclosed
WO-2007019083-A1 PYRIMIDINE COMPOUNDS AS SEROTONIN RECEPTOR MODULATORS JANSSEN PHARMACEUTICA N.V. (BE) 2007-02-15 — — WO disclosed
US-20070032481-A1 PYRIMIDINE COMPOUNDS AS SEROTONIN RECEPTOR MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2007-02-08 — — US disclosed
US-6914140-B1 Asymmetric synthesis process HOFFMANN-LA ROCHE INC. (US) 2005-07-05 — — US disclosed
US-6069245-A PRODUCING A 3-BENZOYLAMINO-4-BENZOYLOXYHEXAHYDROAZEPINE BY THE CATALYTIC HYDROGENATION OF THE 4-OXO-AMINE SALT DERIVATIVE; PROTECTING THE RING NITROGEN; FORMING A FUSED RING; HYDROLYSIS; ACYLATION AND DEPROTECTING HOFFMANN-LA ROCHE INC. (US) 2000-05-30 — — US disclosed
US-5902882-A ASYMMETRICALLY HYDROGENATING AN AZEPINE COMPOUND IN THE PRESENCE OF A RUTHENIUM-DIPHOSPHINE COMPLEX CATALYST HOFFMANN-LA ROCHE INC. (US) 1999-05-11 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230096028-A1 BICYCLIC HETEROCYCLYL COMPOUNDS AND USES THEREOF SOST, SOS1, IQGAP1 MAPT 3878/4885ALDH1A1 3359/4885HPGD 844/4885
US-20070032481-A1 PYRIMIDINE COMPOUNDS AS SEROTONIN RECEPTOR MODULATORS HTR1A, HTR5A, HTR6 MAPT 1462/4885ALDH1A1 3160/4885HPGD 900/4885
US-20100016281-A1 PYRIMIDINE COMPOUNDS AS SEROTONIN RECEPTOR MODULATORS HTR1A, HTR5A, HTR6 MAPT 1462/4885ALDH1A1 3160/4885HPGD 900/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.